Back to mobile site

UBS Reiterates a 'Buy' on Johnson & Johnson (JNJ); Diving Into Valuation

August 1, 2012 12:10 PM EDT
Get Alerts JNJ Hot Sheet
Price: $260.35 -0.66%

Rating Summary:
    23 Buy, 11 Hold, 2 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
UBS reiterates a 'Buy' on Johnson & Johnson (NYSE: JNJ) price target of $76.00 (from $70.00).

Analyst, Rajeev Jashnani, said, "Proabably the biggest point of contention that we hear on JNJ relates to valuation. While the stock does trade at 10% & 8% premiums to US large cap med tech & pharma groups, it is not clear to us that these broad averages are relevant comps. In med tech, JNJ has less exposure to sluggish cardio/ortho end-markets. In pharma, outlook vs. US peers is also fairly wide, as JNJ revs could grow at 6% over next 3 yrs vs. flattish for the broader group. JNJ trades at a ~30% discount to consumer.

For an analyst ratings summary and ratings history on Johnson & Johnson click here. For more ratings news on Johnson & Johnson click here.

Shares of Johnson & Johnson closed at $69.22 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change

Related Entities

UBS